Építés alatt – nem éles oldal
Belépés
Fut, nem toborozFázis nélkül

Therapy and Peer Support for Patients Taking Medication for Opioid Use Disorder

A legfontosabb adatok

Ki végzi
Philadelphia College of Osteopathic Medicine
Hol
Atlantic City és Philadelphia (Egyesült Államok)Mind a 5 helyszín megnézése
Azonosító
Állapot
Fut, nem toboroz
Résztvevők
340 fő vett részt
Kezdés
2020. júl. 15.
Befejezés
2026. jún. 30.
A vizsgálat típusa
Beavatkozással járó, 4 csoportAz egyik csoport egy már használt kezelést kap, összehasonlításként.
A vizsgált kezelések
  • Psychosocial treatment
A regiszteradat frissítve
2025. július 31.

Ki vehet részt

Életkor
18 év felett
Nem
Nők és férfiak
Egészséges önkéntesek
Nem vehetnek részt

A regiszter feltételei, szó szerint

Mind a 18 feltétel megnézéseKevesebb

Ki vehet részt

  • Adults (≥18 years)
  • Be deemed eligible for buprenorphine treatment for OUD by the FQHC treatment provider and agree to engage in this treatment
  • Not require an inpatient level of care as determined by the healthcare provider
  • Be capable of providing valid contact information and informed consent; and
  • Permit the research team to use and disclose their protected health information (PHI)

Ki nem vehet részt

  • Individuals who are intoxicated, cognitively impaired, or psychiatrically unstable at baseline will not be included; however, they may subsequently be included if the disqualifying condition subsides
  • Withdrawal. Moderate OUD severity is denoted by the presence of 4 or 5 of these symptoms and severe OUD is denoted by 6 or more symptoms. Patients will be excluded from the study if their SUD is primarily for a different substance, or their co-morbid psychiatric needs indicate enhanced needs
  • DSM 5 criteria for OUD include:
  • Taking opioids in larger amounts or longer than intended
  • Failed efforts to quit or cut back
  • Spending a lot of time obtaining the opioid
  • Craving or urges to use
  • Repeated inability to carry out major work, school, or home obligations
  • Continued use despite persistent or recurring interpersonal problems worsened by opioid use
  • Stopping or reducing important social, recreational activities due to opioid use
  • Recurrent use of opioids in physically hazardous situations
  • Continued opioid use despite knowledge of having a persistent or recurrent physical or psychological problem that is likely to have been caused or exacerbated by the substance
  • Tolerance; and

Helyszínek itt: Egyesült Államok

  • AtlantiCareAtlantic City, Egyesült Államok
  • Berks Community Health CenterPhiladelphia, Egyesült Államok
  • Care ClinicPhiladelphia, Egyesült Államok
  • Delaware Valley Community HealthPhiladelphia, Egyesült Államok
  • Philadelphia FIGHTPhiladelphia, Egyesült Államok

A vizsgálatról

Mit akar kideríteni a vizsgálat

Current clinical guidelines for medication assisted treatment (MAT) of opioid use disorder (OUD) recommend that treatment include a psychosocial component to help address psychological factors related to addiction. However, a knowledge gap exists regarding the most effective forms of psychosocial intervention and what interventions are most effective for different types of patients. This gap represents a significant barrier to the widespread implementation of effective office-based opioid treatment (OBOT) with buprenorphine, which is important to improving opioid treatment and responding to the critical needs of individuals living with OUD. The overarching goal of this patient-centered research is to address the diverse needs and preferences of OUD patients in regards to psychosocial approaches and to overcome the "one-size-fits-all" strategies that are typically used to treat OUD. Importantly, investigators arrived at this goal, in part, through collaboration and consultation with former patients who have received different types of treatments for OUD. In this manner, patients provided important insight to inform the selection of interventions to be evaluated, patient characteristics that may differentially impact the effects of the interventions, and the patient outcomes to be examined.

A vizsgálat 4 csoportja

  • Treatment as usualNincs vizsgálati kezelés, összehasonlításként

    Those randomized to treatment as usual will receive standard treatment from one of four FQHC sites.

  • Office based CBTMár használt kezelés, összehasonlításként

    Those randomized to Cognitive Behavioral Treatment will receive cognitive behavioral treatment (CBT) along with standard treatment from the FQHC.

    Kezelés: Psychosocial treatment

  • CRS/CPSMár használt kezelés, összehasonlításként

    Those randomized to certified recovery specialist(CRS)/peer support specialist(CPS) will receive a CRS/CPS along with standard treatment from the FQHC.

    Kezelés: Psychosocial treatment

  • CBT+CRS/CPSMár használt kezelés, összehasonlításként

    Those randomized to MAT+ office-based CBT will receive office-based buprenorphine treatment along with office-based CBT and a CRS.

    Kezelés: Psychosocial treatment

Adatok és források

Regiszteradat
Szerepel a ClinicalTrials.gov-on.
Hivatalos cím
Identifying Optimal Psychosocial Interventions for Patients Receiving Office-Based Buprenorphine
Publikációk
A regiszteradat frissítve
2025. július 31.